Meet the team behind every trial

Dr Francis has 10+ years of clinical and translational research experience. He is a Pharmaceutical Physician, and fellow of the Royal College of Physicians (UK).

He has lead 100+ trials as a Principal investigator and served as an investigator on 300+.  He specialises in First in Human and Early phase trials, with extensive experience in trial strategy, protocol design, and safety monitoring. He has chaired over 50 safety review committees.

His PhD explored the role of novel stem cell-based therapy for cartilage repair. He has a strong interest in pharmaceutical medicine, drug development, and translational medicine.

‍

Dr. Priya Loomba is a Sydney-based medical professional with over 20 years’ experience across metropolitan, rural, and Indigenous healthcare settings, with strong insight into diverse patient communities.

An Investigator at Emeritus Research Sydney and working part-time in General Practice, she has contributed to more than 85 clinical trials, bridging frontline care with evidence-based research.

Her interests include sexual health, LGBTQ+ care, women’s and men’s health, preventative medicine and vaccine optimisation, weight loss and metabolic disease, chronic disease management, mental health, and improving clinical trial quality.

She is passionate about improving participant access, reducing participant burden, and strengthening Australia’s women’s health ecosystem. A published author in the Journal of Sexual Health, she is completing The RACGP dermatology certification, expanding her skills in skin health and therapeutic dermatology.

‍

Dr Ronald Mak is a Principal Investigator with a background in Australian primary care. Between 2016 and 2023, he worked in general practice, providing comprehensive care across a wide spectrum of medical conditions.

Dr Mak transitioned into clinical research in 2025 and has rapidly developed substantial trial experience, serving as a Sub-Investigator on more than 30 studies and as Principal Investigator on 9 studies since January 2026. His experience spans participant recruitment, safety monitoring, protocol management, and cross-functional collaboration with sponsors and CROs. Drawing on his extensive primary care background, Dr Mak brings a patient-centred approach to clinical research and is dedicated to delivering high-quality study outcomes while maintaining regulatory and ethical standards.

Dr Bronia Lewis has been involved in clinical trials since 2022. During this time she has led 5 clinical trials as a Principal Investigator and contributed to over 145 clinical trials as a Sub-Investigator.

Prior to working in clinical research she gained 8 years of medical experience in a wide range of specialities including emergency medicine, intensive care, general medicine and paediatrics.

Her areas of special interest are early phase trials, cardiovascular disease and mental health. She is passionate about education, having completed a Masters of Teaching, and enjoys being involved in investigator training.

Dr Conor Cusack is a Pharmaceutical Physician with experience as an investigator in more than 80 clinical trials since 2022, including first-in-human and early-phase trials, controlled human infection models, and Phase 1-3 vaccine trials. He has also worked in sponsor-facing roles at the CRO level, advising on clinical development strategy, regulatory pathways, and protocol design.

Dr Cusack holds the Diploma in Pharmaceutical Medicine and Membership of the Faculty of Pharmaceutical Medicine (Royal College of Physicians, UK), reflecting specialist training in drug development. His earlier clinical work in Emergency and General Medicine, Surgery, and Psychiatry, provides a strong foundation for safety oversight and risk assessment in complex trials.

He has interests in early clinical development and translational medicine, immunology and endocrinology.

Dr Shah has 5+ years of clinical and research experience. He is a Principal Investigator on 20+ studies and a Sub-Investigator on 60+ studies. He has extensive experience with safety monitoring, protocol development and study design.

His research portfolio includes high-volume vaccine and therapeutic trials, including monoclonal antibodies, biologics, and genetically modified organisms (GMOs). He has Phase I–III studies, including first-in-human (FIH) and early phase experience.

Dr Shah has a strong interest in improving long-term outcomes of chronic disease, particularly in cardio-metabolic medicine, gastroenterology, and neurology.

Dr Justin Tan is an Australian medical doctor (Monash 2021) with experience across 50+ Phase I–III clinical trials (6 as a Principal Investigator, 51 as a Sub Investigator), specializing in vaccines, metabolic disease, recruitment optimization for high volume studies.

His trial background spans across multiple therapeutic specialties including but not limited to dermatologic biologics, vaccine trials, obesity studies, and gout therapeutics.

Dr Tan enjoys employing a problem-solving approach towards navigating the intricacies and nuances of each study, ensuring customised solutions with quality deliverables.

Dr Raf Malik is an Australian medical doctor (UQ 2017) with experience across Phase I–III clinical trials, specializing in dermatology, vaccines, metabolic disease, and aesthetic medicine. His trial background includes acne, atopic dermatitis, alopecia, dermatologic biologics, vaccine trials, obesity studies, and gout therapeutics. He also brings several years of procedural experience in hair transplantation (FUT/FUE) and regenerative scalp therapies alongside formal training in cosmetic injectables.

He is trained in alopecia assessment and is a certified SALT (Severity of Alopecia Tool) scorer, providing objective and standardized evaluation for hair-loss studies.

Dr Michelle Bassin has been working in clinical trials since 2021, during which time she has been a sub-investigator on over 80 trials, including first in human, vaccine and therapeutic trials.

Michelle brings a broad range of clinical experience to her work in clinical trials, having worked in metropolitan and regional hospitals in multiple internal medicine sub-specialties, in quarantine medicine during the COVID19 pandemic and currently works part-time as a recruiting medical officer for the Australian Defence Force.

Michelle has a Master of Public Health and is passionate about the broad reach clinical trials have in improving health at a population level.

Dr Sewa Rijal has 10+ years of clinical, academic, and translational research experience. She is a clinician-scientist with an MD from the Australian National University and a PhD in haematological malignancies from Monash University, with a strong background in translational oncology research and clinical trials.

She has served as a sub-investigator on several clinical trials and brings a strong background in academic trial-linked research. Her doctoral work was embedded within active clinical trial programs, focusing on biomarker research and translational medicine. Her clinical trial experience spans Phase I to Phase III studies, with involvement in participant eligibility assessment, informed consent, protocol delivery, safety monitoring, adverse event review, and sponsor-facing clinical oversight. She has authored multiple peer-reviewed publications, presented at international conferences, and received competitive research awards and grants. She has a strong interest in pharmaceutical medicine, drug development, translational medicine, precision medicine, oncology, obesity, cardiometabolic disease, women’s health, and community-based clinical research.